RAD21 and inflammatory skin disease: Thus, the combined effect of impaired transcriptional regulation (i.e., a mutation in RAD21) and enhanced inflammatory signaling (i.e., a mutation in TNFAIP3) may explain the coexistence of developmental abnormalities (CdLS) and inflammatory skin disease (pustular psoriasis) in the same patient [22].